COMPANY

Aardvark Therapeutics

HQ: San Diego, CA source · aardvarktherapeutics.com ↗

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing, small-molecule therapies designed to inhibit hunger and treat metabolic diseases. Aardvark is developing compounds that target Bitter Taste Receptors (TAS2Rs) to address hunger-associated conditions. From company website Source · Oct 13, 2026

Keywords: clinical-stage Prader-Willi Syndrome Hyperphagia Obesity Hyperphagia in Prader-Willi Syndrome Autism Spectrum Disorder Bariatric Surgery Weight Gain ARD-101

Location: San Diego, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$94.2MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Feb 13, 2025 Raise IPO: $94.2M (total, as published), announced Feb 13, 2025. Source: company release on GlobeNewswire. source ↗
Dec 20, 2024 Trial start Phase 3: ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial source ↗
Aug 1, 2024 Trial start Phase 2: A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder source ↗
Jul 23, 2024 Trial start Phase 3: The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial source ↗
May 27, 2022 Trial start Phase 2: A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome source ↗
Mar 1, 2022 Trial start Phase 2: Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery source ↗
Nov 15, 2021 Trial start Phase 2: Study to Evaluate ARD-101 in Adults With Obesity source ↗

Funding

Raised: $94.2M. Last 2 years.

Feb 13, 2025 IPO: $94.2M (total, as published), announced Feb 13, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT05153434	A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome	Phase 2	Completed	May 27, 2022	Sep 24, 2024 (actual)
NCT06828861	ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial	Phase 3	Terminated	Dec 20, 2024	May 7, 2026 (actual)
NCT07197034	The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial	Phase 3	Terminated	Jul 23, 2024	Apr 15, 2026 (actual)
NCT06126653	A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder	Phase 2	Completed	Aug 1, 2024	Jan 13, 2025 (actual)
NCT05215847	Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery	Phase 2	Completed	Mar 1, 2022	Feb 3, 2023 (actual)
NCT05121441	Study to Evaluate ARD-101 in Adults With Obesity	Phase 2	Completed	Nov 15, 2021	Nov 9, 2022 (actual)

Connect

Contact page